Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3932043,serum protein binding,The serum protein binding of the free acid metabolite of misoprostol was similar in young (81-88%) and elderly (81-89%) people.,Metabolism and pharmacokinetic studies of misoprostol. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932043/),%,81-88,993,DB00770,Alprostadil
,3932043,serum protein binding,The serum protein binding of the free acid metabolite of misoprostol was similar in young (81-88%) and elderly (81-89%) people.,Metabolism and pharmacokinetic studies of misoprostol. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3932043/),%,81-89,994,DB00770,Alprostadil
,17882966,Tmax,"Tmax was found to be approximately 3-4 min for nasal route, 3-8 min for im, 6-8 min for ip and 12-30 min for sublingual route, separately.",Pharmacodynamic comparison of prostaglandin E1 administered by different routes to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17882966/),min,3-4,2612,DB00770,Alprostadil
,17882966,Tmax,"Tmax was found to be approximately 3-4 min for nasal route, 3-8 min for im, 6-8 min for ip and 12-30 min for sublingual route, separately.",Pharmacodynamic comparison of prostaglandin E1 administered by different routes to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17882966/),min,3-8,2613,DB00770,Alprostadil
,17882966,Tmax,"Tmax was found to be approximately 3-4 min for nasal route, 3-8 min for im, 6-8 min for ip and 12-30 min for sublingual route, separately.",Pharmacodynamic comparison of prostaglandin E1 administered by different routes to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17882966/),min,6-8,2614,DB00770,Alprostadil
,17882966,Tmax,"Tmax was found to be approximately 3-4 min for nasal route, 3-8 min for im, 6-8 min for ip and 12-30 min for sublingual route, separately.",Pharmacodynamic comparison of prostaglandin E1 administered by different routes to rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17882966/),min,12-30,2615,DB00770,Alprostadil
,21530623,entrapment efficiency,Incorporation of PEI in the formulations resulted in an increased entrapment efficiency - 83.26 ± 3.04% for particles with 1% PVA and 95.48 ± 0.46% for particles with 2% PVA.,"Influence of PEI as a core modifying agent on PLGA microspheres of PGE₁, a pulmonary selective vasodilator. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21530623/),%,83.26,6650,DB00770,Alprostadil
,21530623,entrapment efficiency,Incorporation of PEI in the formulations resulted in an increased entrapment efficiency - 83.26 ± 3.04% for particles with 1% PVA and 95.48 ± 0.46% for particles with 2% PVA.,"Influence of PEI as a core modifying agent on PLGA microspheres of PGE₁, a pulmonary selective vasodilator. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21530623/),%,95.48,6651,DB00770,Alprostadil
,21530623,amount of cumulative drug released,The amount of cumulative drug released into the simulated interstitial lung fluid was between 50.8 ± 0.76% and 55.36 ± 0.06%.,"Influence of PEI as a core modifying agent on PLGA microspheres of PGE₁, a pulmonary selective vasodilator. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21530623/),%,50.8,6652,DB00770,Alprostadil
,21530623,amount of cumulative drug released,The amount of cumulative drug released into the simulated interstitial lung fluid was between 50.8 ± 0.76% and 55.36 ± 0.06%.,"Influence of PEI as a core modifying agent on PLGA microspheres of PGE₁, a pulmonary selective vasodilator. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21530623/),%,55.36,6653,DB00770,Alprostadil
up,21530623,circulation half-life,A remarkable extension of the circulation half-life up to 6.0-6.5h was observed when the formulations were administered via the lungs.,"Influence of PEI as a core modifying agent on PLGA microspheres of PGE₁, a pulmonary selective vasodilator. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21530623/),h,6.0-6.5,6654,DB00770,Alprostadil
,1708425,steady-state plasma t-PA clearance,"In a separate series of experiments, steady-state plasma t-PA clearance increased by 38% (407 +/- 49 vs. 294 +/- 42 ml/min; n = 8, P less than .02) during infusion of iloprost and recovered after its withdrawal.",A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1708425/),[ml] / [min],407,17408,DB00770,Alprostadil
,1708425,steady-state plasma t-PA clearance,"In a separate series of experiments, steady-state plasma t-PA clearance increased by 38% (407 +/- 49 vs. 294 +/- 42 ml/min; n = 8, P less than .02) during infusion of iloprost and recovered after its withdrawal.",A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1708425/),[ml] / [min],294,17409,DB00770,Alprostadil
,1750222,half-life,"13,14-dihydro-PGE1 degraded like PGE1 in human plasma at 37 degrees C with a half-life of several hours.",[Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1750222/),h,several,19088,DB00770,Alprostadil
,7708804,Basal levels,Basal levels of PGE-M were 64.05 +/- 34.17 pg/ml.,"Gas chromatography/negative ion chemical ionization triple quadrupole mass spectrometric determination and pharmacokinetics of 11 alpha-hydroxy-9,15-dioxo-2,3,4,5,20-pentanor-19-carboxyprostan oic acid in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7708804/),[pg] / [ml],64.05,39984,DB00770,Alprostadil
,7708804,maximum levels,"After infusion of 120 micrograms prostaglandin E1 (PGE1) in six subjects in 15 min, maximum levels of PGE-M of 618.6 +/- 210.3 pg/ml were reached 20-45 min after the end of infusion.","Gas chromatography/negative ion chemical ionization triple quadrupole mass spectrometric determination and pharmacokinetics of 11 alpha-hydroxy-9,15-dioxo-2,3,4,5,20-pentanor-19-carboxyprostan oic acid in plasma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7708804/),[pg] / [ml],618.6,39985,DB00770,Alprostadil
,7708804,half-life,PGE-M has a half-life of 8.96 +/- 3.53 min for formation and 31.71 +/- 6.39 min for elimination.,"Gas chromatography/negative ion chemical ionization triple quadrupole mass spectrometric determination and pharmacokinetics of 11 alpha-hydroxy-9,15-dioxo-2,3,4,5,20-pentanor-19-carboxyprostan oic acid in plasma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7708804/),min,8.96,39986,DB00770,Alprostadil
,7708804,half-life,PGE-M has a half-life of 8.96 +/- 3.53 min for formation and 31.71 +/- 6.39 min for elimination.,"Gas chromatography/negative ion chemical ionization triple quadrupole mass spectrometric determination and pharmacokinetics of 11 alpha-hydroxy-9,15-dioxo-2,3,4,5,20-pentanor-19-carboxyprostan oic acid in plasma. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7708804/),min,31.71,39987,DB00770,Alprostadil
,6185792,terminal half-life,"13,14-Dihydro-15-keto-PGE1 plasma concentrations were proportional to the dose in all experiments and they declined biexponentially with a terminal half-life ranging from 25 to 34 min.",In vivo disposition of prostaglandin E1 via pharmacokinetic characterization of its pulmonary metabolite. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6185792/),min,25 to 34,46503,DB00770,Alprostadil
,6185792,clearance,Typical clearance values were 10-14 ml/kg/min.,In vivo disposition of prostaglandin E1 via pharmacokinetic characterization of its pulmonary metabolite. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6185792/),[ml] / [kg·min],10-14,46504,DB00770,Alprostadil
,19825922,detection,Blood samples were obtained at 14 consecutive time points for 12 hours after dosing and analyzed by liquid chromatography-tandem mass spectrometry with electrospray ionization (LC-ESI/MS/ MS) at a very low detection limit of 0.5 pg/mL of limaprost in human plasma with considerably short run time (18 minutes).,"Pharmacokinetic characteristics of a vasodilatory and antiplatelet agent, limaprost alfadex, in the healthy Korean volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825922/),[pg] / [ml],0.5,56968,DB00770,Alprostadil
,19825922,run time,Blood samples were obtained at 14 consecutive time points for 12 hours after dosing and analyzed by liquid chromatography-tandem mass spectrometry with electrospray ionization (LC-ESI/MS/ MS) at a very low detection limit of 0.5 pg/mL of limaprost in human plasma with considerably short run time (18 minutes).,"Pharmacokinetic characteristics of a vasodilatory and antiplatelet agent, limaprost alfadex, in the healthy Korean volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825922/),min,18,56969,DB00770,Alprostadil
,19825922,time for maximal concentrations (T(max),"Pharmacokinetic characteristics resulted in ''time for maximal concentrations (T(max) 0.5 hour),'' ''elimination half-life (T(1/2) 1.64 hours),'' ''maximal concentration (C(max) 13.37 pg/mL),'' ''area under the curve (AUC(12 hours) 18.60 pg . h/mL),'' ''AUC extrapolated to infinity (AUC(infinity) 22.98 pg . h/mL),'' ''extrapolation (AUC(infinity - 12 hours)/AUC(infinity) 0.15%),'' ''elimination rate constant (k(e) 0.68 h(-1)),'' ''systemic clearance (CL 1.77 L/h),'' and ''mean residence time (MRT 1.74 hours).''","Pharmacokinetic characteristics of a vasodilatory and antiplatelet agent, limaprost alfadex, in the healthy Korean volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825922/),h,0.5,56970,DB00770,Alprostadil
,19825922,elimination half-life (T(1/2),"Pharmacokinetic characteristics resulted in ''time for maximal concentrations (T(max) 0.5 hour),'' ''elimination half-life (T(1/2) 1.64 hours),'' ''maximal concentration (C(max) 13.37 pg/mL),'' ''area under the curve (AUC(12 hours) 18.60 pg . h/mL),'' ''AUC extrapolated to infinity (AUC(infinity) 22.98 pg . h/mL),'' ''extrapolation (AUC(infinity - 12 hours)/AUC(infinity) 0.15%),'' ''elimination rate constant (k(e) 0.68 h(-1)),'' ''systemic clearance (CL 1.77 L/h),'' and ''mean residence time (MRT 1.74 hours).''","Pharmacokinetic characteristics of a vasodilatory and antiplatelet agent, limaprost alfadex, in the healthy Korean volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825922/),h,1.64,56971,DB00770,Alprostadil
,19825922,maximal concentration (C(max),"Pharmacokinetic characteristics resulted in ''time for maximal concentrations (T(max) 0.5 hour),'' ''elimination half-life (T(1/2) 1.64 hours),'' ''maximal concentration (C(max) 13.37 pg/mL),'' ''area under the curve (AUC(12 hours) 18.60 pg . h/mL),'' ''AUC extrapolated to infinity (AUC(infinity) 22.98 pg . h/mL),'' ''extrapolation (AUC(infinity - 12 hours)/AUC(infinity) 0.15%),'' ''elimination rate constant (k(e) 0.68 h(-1)),'' ''systemic clearance (CL 1.77 L/h),'' and ''mean residence time (MRT 1.74 hours).''","Pharmacokinetic characteristics of a vasodilatory and antiplatelet agent, limaprost alfadex, in the healthy Korean volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825922/),[pg] / [ml],13.37,56972,DB00770,Alprostadil
,19825922,area under the curve (AUC(12 hours),"Pharmacokinetic characteristics resulted in ''time for maximal concentrations (T(max) 0.5 hour),'' ''elimination half-life (T(1/2) 1.64 hours),'' ''maximal concentration (C(max) 13.37 pg/mL),'' ''area under the curve (AUC(12 hours) 18.60 pg . h/mL),'' ''AUC extrapolated to infinity (AUC(infinity) 22.98 pg . h/mL),'' ''extrapolation (AUC(infinity - 12 hours)/AUC(infinity) 0.15%),'' ''elimination rate constant (k(e) 0.68 h(-1)),'' ''systemic clearance (CL 1.77 L/h),'' and ''mean residence time (MRT 1.74 hours).''","Pharmacokinetic characteristics of a vasodilatory and antiplatelet agent, limaprost alfadex, in the healthy Korean volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825922/),[h·pg] / [ml],18.60,56973,DB00770,Alprostadil
,19825922,elimination rate constant (k(e),"Pharmacokinetic characteristics resulted in ''time for maximal concentrations (T(max) 0.5 hour),'' ''elimination half-life (T(1/2) 1.64 hours),'' ''maximal concentration (C(max) 13.37 pg/mL),'' ''area under the curve (AUC(12 hours) 18.60 pg . h/mL),'' ''AUC extrapolated to infinity (AUC(infinity) 22.98 pg . h/mL),'' ''extrapolation (AUC(infinity - 12 hours)/AUC(infinity) 0.15%),'' ''elimination rate constant (k(e) 0.68 h(-1)),'' ''systemic clearance (CL 1.77 L/h),'' and ''mean residence time (MRT 1.74 hours).''","Pharmacokinetic characteristics of a vasodilatory and antiplatelet agent, limaprost alfadex, in the healthy Korean volunteers. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825922/),1/[h],0.68,56974,DB00770,Alprostadil
,19825922,systemic clearance (CL,"Pharmacokinetic characteristics resulted in ''time for maximal concentrations (T(max) 0.5 hour),'' ''elimination half-life (T(1/2) 1.64 hours),'' ''maximal concentration (C(max) 13.37 pg/mL),'' ''area under the curve (AUC(12 hours) 18.60 pg . h/mL),'' ''AUC extrapolated to infinity (AUC(infinity) 22.98 pg . h/mL),'' ''extrapolation (AUC(infinity - 12 hours)/AUC(infinity) 0.15%),'' ''elimination rate constant (k(e) 0.68 h(-1)),'' ''systemic clearance (CL 1.77 L/h),'' and ''mean residence time (MRT 1.74 hours).''","Pharmacokinetic characteristics of a vasodilatory and antiplatelet agent, limaprost alfadex, in the healthy Korean volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825922/),[l] / [h],1.77,56975,DB00770,Alprostadil
,19825922,mean residence time (MRT,"Pharmacokinetic characteristics resulted in ''time for maximal concentrations (T(max) 0.5 hour),'' ''elimination half-life (T(1/2) 1.64 hours),'' ''maximal concentration (C(max) 13.37 pg/mL),'' ''area under the curve (AUC(12 hours) 18.60 pg . h/mL),'' ''AUC extrapolated to infinity (AUC(infinity) 22.98 pg . h/mL),'' ''extrapolation (AUC(infinity - 12 hours)/AUC(infinity) 0.15%),'' ''elimination rate constant (k(e) 0.68 h(-1)),'' ''systemic clearance (CL 1.77 L/h),'' and ''mean residence time (MRT 1.74 hours).''","Pharmacokinetic characteristics of a vasodilatory and antiplatelet agent, limaprost alfadex, in the healthy Korean volunteers. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825922/),h,1.74,56976,DB00770,Alprostadil
,12972009,half-life,In amniotic fluid the half-life was between 31 and 37 hours.,Pharmacokinetics of prostaglandins. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12972009/),h,31 and 37,72670,DB00770,Alprostadil
,1738412,Uosm,"Higher PGE1 infusion rates (0.05 and 0.1 micrograms/min/kg) were associated with a progressive increase of FCurea (50%, p less than 0.001 and 91%, p less than 0.001, respectively), fractional clearance of water and salt output, inulin and PAH clearance and reduced Uosm from 1,005 (22 SEM; basal value) to 772 (38 SEM; minimum value) mosm/kg (p less than 0.001).",Inhibition of urea tubular reabsorption by PGE1 infusion in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1738412/),[mosm] / [kg],"1,005",93491,DB00770,Alprostadil
,1738412,Uosm,"Higher PGE1 infusion rates (0.05 and 0.1 micrograms/min/kg) were associated with a progressive increase of FCurea (50%, p less than 0.001 and 91%, p less than 0.001, respectively), fractional clearance of water and salt output, inulin and PAH clearance and reduced Uosm from 1,005 (22 SEM; basal value) to 772 (38 SEM; minimum value) mosm/kg (p less than 0.001).",Inhibition of urea tubular reabsorption by PGE1 infusion in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1738412/),[mosm] / [kg],772,93492,DB00770,Alprostadil
,2873999,half-life,"Following iv administration, ONO-802 was rapidly hydrolyzed to the free acid which disappeared from plasma with an approximate half-life of 10-15 min.","Metabolism of 16, 16-dimethyl-trans-delta 2-prostaglandin E1 methyl ester (ONO-802) following intravenous and vaginal administration to pregnant women. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2873999/),min,10-15,98149,DB00770,Alprostadil
,2506635,Emax,Laser-Doppler flowmetry measured a dose-dependent increase in blood flow (Emax = 6.4 +/- 2.8 V at the 100-micrograms dose; equivalent to 92.8% increase above the basal mean blood flow value; ED50 = 1.0 micrograms).,The dose-response of canine focal gastric mucosal blood flow to misoprostol. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2506635/),v,6.4,112499,DB00770,Alprostadil
,2506635,ED50,Laser-Doppler flowmetry measured a dose-dependent increase in blood flow (Emax = 6.4 +/- 2.8 V at the 100-micrograms dose; equivalent to 92.8% increase above the basal mean blood flow value; ED50 = 1.0 micrograms).,The dose-response of canine focal gastric mucosal blood flow to misoprostol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2506635/),μg,1.0,112500,DB00770,Alprostadil
,18218297,AUC0-t,"The means of AUC0-t were 0.779 vs. 0.754 pg x h/ml (test vs. reference), and the means of the Cmax were 1.26 vs. 1.12 pg/ml (test vs. reference).",Bioequivalence study of two limaprost alfadex 5 microg tablets in healthy subjects: moisture-resistant tablet (dextran formulation) versus standard tablet (lactose formulation). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18218297/),[h·pg] / [ml],0.779,129157,DB00770,Alprostadil
,18218297,AUC0-t,"The means of AUC0-t were 0.779 vs. 0.754 pg x h/ml (test vs. reference), and the means of the Cmax were 1.26 vs. 1.12 pg/ml (test vs. reference).",Bioequivalence study of two limaprost alfadex 5 microg tablets in healthy subjects: moisture-resistant tablet (dextran formulation) versus standard tablet (lactose formulation). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18218297/),[h·pg] / [ml],0.754,129158,DB00770,Alprostadil
,18218297,Cmax,"The means of AUC0-t were 0.779 vs. 0.754 pg x h/ml (test vs. reference), and the means of the Cmax were 1.26 vs. 1.12 pg/ml (test vs. reference).",Bioequivalence study of two limaprost alfadex 5 microg tablets in healthy subjects: moisture-resistant tablet (dextran formulation) versus standard tablet (lactose formulation). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18218297/),[pg] / [ml],1.26,129159,DB00770,Alprostadil
,18218297,Cmax,"The means of AUC0-t were 0.779 vs. 0.754 pg x h/ml (test vs. reference), and the means of the Cmax were 1.26 vs. 1.12 pg/ml (test vs. reference).",Bioequivalence study of two limaprost alfadex 5 microg tablets in healthy subjects: moisture-resistant tablet (dextran formulation) versus standard tablet (lactose formulation). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18218297/),[pg] / [ml],1.12,129160,DB00770,Alprostadil
,8070511,plasma concentrations,Endogenous PGE1 plasma concentrations ranged between 1.2 and 1.8 pg.,Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8070511/),pg,1.2 and 1.8,147400,DB00770,Alprostadil
,2825745,terminal half life,"The concentrations declined in a biexponential fashion, with a terminal half life of 24.1 +/- 1.9 h (mean +/- s.e. mean).",Dipyridamole: pharmacokinetics and effects on aspects of platelet function in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2825745/),h,24.1,152727,DB00770,Alprostadil
,8835565,concentrations required for 50% inhibition (EC50),Data from the single dose study revealed that the mean (+/- SD) of the concentrations required for 50% inhibition (EC50) of platelet derived TXB2 by total naproxen was 7.7 +/- 4.4 micrograms/ml (n = 5) and for unbound drug 25.4 +/- 22.0 ng/ml (n = 5).,Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835565/),[μg] / [ml],7.7,154890,DB00770,Alprostadil
,8835565,unbound drug,Data from the single dose study revealed that the mean (+/- SD) of the concentrations required for 50% inhibition (EC50) of platelet derived TXB2 by total naproxen was 7.7 +/- 4.4 micrograms/ml (n = 5) and for unbound drug 25.4 +/- 22.0 ng/ml (n = 5).,Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8835565/),[ng] / [ml],25.4,154891,DB00770,Alprostadil
,11324717,constant flow rate,The liver was perfused in a recirculating system at a constant flow rate of 20 ml/min.,The effects of norepinephrine and prostaglandin E1 on pharmacokinetics of lidocaine in isolated perfused rat liver. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11324717/),[ml] / [min],20,159488,DB00770,Alprostadil
,19217739,flow rate,"After a simple sample preparation procedure involving a one-step liquid-liquid extraction, alprostadil and the internal standard, diphenhydramine, were chromatographed on an ACQUITY UPLC BEH C(18) column with gradient elution using a mobile phase consisting of acetonitrile and water (containing 0.1% formic acid) at a flow rate of 0.25 mL min(-1).",Determination of alprostadil in rat plasma by ultra performance liquid chromatography-electrospray ionization-tandem mass spectrometry after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19217739/),[ml] / [min],0.25,161894,DB00770,Alprostadil
,25586152,time to reach maximum plasma concentration [t max],"After single dosing, limaprost was rapidly absorbed (time to reach maximum plasma concentration [t max] = 22.50 min) and eliminated (elimination half-life [t ½] = 21.70 min), with the maximum plasma concentration (C max) being 2.56 pg/mL and area under the concentration-time curve (AUC) from time 0 to the last quantifiable time point (AUC0-t) being 70.68 pg·min/mL.",Single- and multiple-dose pharmacokinetics and tolerability of limaprost in healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586152/),min,22.50,165439,DB00770,Alprostadil
,25586152,elimination half-life [t ½],"After single dosing, limaprost was rapidly absorbed (time to reach maximum plasma concentration [t max] = 22.50 min) and eliminated (elimination half-life [t ½] = 21.70 min), with the maximum plasma concentration (C max) being 2.56 pg/mL and area under the concentration-time curve (AUC) from time 0 to the last quantifiable time point (AUC0-t) being 70.68 pg·min/mL.",Single- and multiple-dose pharmacokinetics and tolerability of limaprost in healthy Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586152/),min,21.70,165440,DB00770,Alprostadil
,25586152,maximum plasma concentration (C max),"After single dosing, limaprost was rapidly absorbed (time to reach maximum plasma concentration [t max] = 22.50 min) and eliminated (elimination half-life [t ½] = 21.70 min), with the maximum plasma concentration (C max) being 2.56 pg/mL and area under the concentration-time curve (AUC) from time 0 to the last quantifiable time point (AUC0-t) being 70.68 pg·min/mL.",Single- and multiple-dose pharmacokinetics and tolerability of limaprost in healthy Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586152/),[pg] / [ml],2.56,165441,DB00770,Alprostadil
,25586152,area under the concentration-time curve (AUC) from time 0 to the last quantifiable time point (AUC0-t),"After single dosing, limaprost was rapidly absorbed (time to reach maximum plasma concentration [t max] = 22.50 min) and eliminated (elimination half-life [t ½] = 21.70 min), with the maximum plasma concentration (C max) being 2.56 pg/mL and area under the concentration-time curve (AUC) from time 0 to the last quantifiable time point (AUC0-t) being 70.68 pg·min/mL.",Single- and multiple-dose pharmacokinetics and tolerability of limaprost in healthy Chinese subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586152/),[min·pg] / [ml],70.68,165442,DB00770,Alprostadil
,24029554,LLOQ,An LLOQ of 10pg/mL was achieved with 500μl plasma.,Determination of Prostaglandin E1 in dog plasma using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24029554/),,10,166564,DB00770,Alprostadil
,24029554,half-life,The half-life was recovered at 7min.,Determination of Prostaglandin E1 in dog plasma using liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24029554/),min,7,166565,DB00770,Alprostadil
,8158764,half-time,"Measurement of the primary metabolite proves a local degradation of prostaglandin E1 in the corpus cavernosum into the biologically inactive 15-keto-13,14-dihydro-prostaglandin E1, which also shows a slight increase in the peripheral circulation due to the longer half-time of approximately 8 minutes.",Pharmacokinetics of vasoactive substances administered into the human corpus cavernosum. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8158764/),min,8,177596,DB00770,Alprostadil
,26149245,limit of detection (LOD),"The method was linear for both analytes in the concentration range 0.05-30ng/mL with intra- and inter-day precisions (as relative standard deviation) of ≤6.75% and accuracy (as relative error) of ≤7.21% and limit of detection (LOD) values were 10 and 20pg/mL, respectively.",Simultaneous determination of carboprost methylate and its active metabolite carboprost in dog plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149245/),[pg] / [ml],10,181544,DB00770,Alprostadil
,26149245,limit of detection (LOD),"The method was linear for both analytes in the concentration range 0.05-30ng/mL with intra- and inter-day precisions (as relative standard deviation) of ≤6.75% and accuracy (as relative error) of ≤7.21% and limit of detection (LOD) values were 10 and 20pg/mL, respectively.",Simultaneous determination of carboprost methylate and its active metabolite carboprost in dog plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149245/),[pg] / [ml],20,181545,DB00770,Alprostadil
,6948952,half-lives,"the metabolite disappeared from the circulation rapidly with half-lives of 9.9 +/- 0.2, 9.2 +/- 0.3 and 7.8 +/- 0.8 min (mean +/- S.E.M., n = 4) for the respective doses noted above.",A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6948952/),min,9.9,182394,DB00770,Alprostadil
,6948952,half-lives,"the metabolite disappeared from the circulation rapidly with half-lives of 9.9 +/- 0.2, 9.2 +/- 0.3 and 7.8 +/- 0.8 min (mean +/- S.E.M., n = 4) for the respective doses noted above.",A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6948952/),min,9.2,182395,DB00770,Alprostadil
,6948952,half-lives,"the metabolite disappeared from the circulation rapidly with half-lives of 9.9 +/- 0.2, 9.2 +/- 0.3 and 7.8 +/- 0.8 min (mean +/- S.E.M., n = 4) for the respective doses noted above.",A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6948952/),min,7.8,182396,DB00770,Alprostadil
,6948952,Basal concentrations,"Basal concentrations of 48 +/- 31 pg/ml (mean +/- S.D., n = 15) in human plasma concur with concentrations measured by gas chromatography/mass spectrometry.",A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: an indirect index of their in vivo disposition and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6948952/),[pg] / [ml],48,182397,DB00770,Alprostadil
,8527291,plasma concentrations,"PGE0 plasma concentrations increased from endogenous levels of 1.3 +/- 1.0 pg ml-1 to 7.6 +/- 2.1, 14.1 +/- 3.7 and 28.0 +/- 3.0 pg ml-1 respectively, whilst 15-keto-PGE0 plasma concentrations increased from endogenous levels of 10.2 +/- 13.9 pg ml-1 to 99.3 +/- 27.9, 190.4 +/- 52.5 and 357.2 +/- 72.6 pg ml-1 respectively.",Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527291/),[pg] / [ml],1.3,186123,DB00770,Alprostadil
,8527291,plasma concentrations,"PGE0 plasma concentrations increased from endogenous levels of 1.3 +/- 1.0 pg ml-1 to 7.6 +/- 2.1, 14.1 +/- 3.7 and 28.0 +/- 3.0 pg ml-1 respectively, whilst 15-keto-PGE0 plasma concentrations increased from endogenous levels of 10.2 +/- 13.9 pg ml-1 to 99.3 +/- 27.9, 190.4 +/- 52.5 and 357.2 +/- 72.6 pg ml-1 respectively.",Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527291/),[pg] / [ml],7.6,186124,DB00770,Alprostadil
,8527291,plasma concentrations,"PGE0 plasma concentrations increased from endogenous levels of 1.3 +/- 1.0 pg ml-1 to 7.6 +/- 2.1, 14.1 +/- 3.7 and 28.0 +/- 3.0 pg ml-1 respectively, whilst 15-keto-PGE0 plasma concentrations increased from endogenous levels of 10.2 +/- 13.9 pg ml-1 to 99.3 +/- 27.9, 190.4 +/- 52.5 and 357.2 +/- 72.6 pg ml-1 respectively.",Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527291/),[pg] / [ml],14.1,186125,DB00770,Alprostadil
,8527291,plasma concentrations,"PGE0 plasma concentrations increased from endogenous levels of 1.3 +/- 1.0 pg ml-1 to 7.6 +/- 2.1, 14.1 +/- 3.7 and 28.0 +/- 3.0 pg ml-1 respectively, whilst 15-keto-PGE0 plasma concentrations increased from endogenous levels of 10.2 +/- 13.9 pg ml-1 to 99.3 +/- 27.9, 190.4 +/- 52.5 and 357.2 +/- 72.6 pg ml-1 respectively.",Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527291/),[pg] / [ml],28.0,186126,DB00770,Alprostadil
,8527291,plasma concentrations,"PGE0 plasma concentrations increased from endogenous levels of 1.3 +/- 1.0 pg ml-1 to 7.6 +/- 2.1, 14.1 +/- 3.7 and 28.0 +/- 3.0 pg ml-1 respectively, whilst 15-keto-PGE0 plasma concentrations increased from endogenous levels of 10.2 +/- 13.9 pg ml-1 to 99.3 +/- 27.9, 190.4 +/- 52.5 and 357.2 +/- 72.6 pg ml-1 respectively.",Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527291/),[pg] / [ml],10.2,186127,DB00770,Alprostadil
,8527291,plasma concentrations,"PGE0 plasma concentrations increased from endogenous levels of 1.3 +/- 1.0 pg ml-1 to 7.6 +/- 2.1, 14.1 +/- 3.7 and 28.0 +/- 3.0 pg ml-1 respectively, whilst 15-keto-PGE0 plasma concentrations increased from endogenous levels of 10.2 +/- 13.9 pg ml-1 to 99.3 +/- 27.9, 190.4 +/- 52.5 and 357.2 +/- 72.6 pg ml-1 respectively.",Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527291/),[pg] / [ml],99.3,186128,DB00770,Alprostadil
,8527291,plasma concentrations,"PGE0 plasma concentrations increased from endogenous levels of 1.3 +/- 1.0 pg ml-1 to 7.6 +/- 2.1, 14.1 +/- 3.7 and 28.0 +/- 3.0 pg ml-1 respectively, whilst 15-keto-PGE0 plasma concentrations increased from endogenous levels of 10.2 +/- 13.9 pg ml-1 to 99.3 +/- 27.9, 190.4 +/- 52.5 and 357.2 +/- 72.6 pg ml-1 respectively.",Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527291/),[pg] / [ml],190.4,186129,DB00770,Alprostadil
,8527291,plasma concentrations,"PGE0 plasma concentrations increased from endogenous levels of 1.3 +/- 1.0 pg ml-1 to 7.6 +/- 2.1, 14.1 +/- 3.7 and 28.0 +/- 3.0 pg ml-1 respectively, whilst 15-keto-PGE0 plasma concentrations increased from endogenous levels of 10.2 +/- 13.9 pg ml-1 to 99.3 +/- 27.9, 190.4 +/- 52.5 and 357.2 +/- 72.6 pg ml-1 respectively.",Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8527291/),[pg] / [ml],357.2,186130,DB00770,Alprostadil
,3337471,pulmonary arterial,"At a dosage rate of 30 ng/kg/min, pulmonary arterial and systemic arterial plasma levels ranged from 265 to 1,009 pg/ml and 50 to 796 pg/ml, respectively.",Pulmonary extraction and pharmacokinetics of prostaglandin E1 during continuous intravenous infusion in patients with adult respiratory distress syndrome. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3337471/),[pg] / [ml],"265 to 1,009",186790,DB00770,Alprostadil
,3337471,plasma levels,"At a dosage rate of 30 ng/kg/min, pulmonary arterial and systemic arterial plasma levels ranged from 265 to 1,009 pg/ml and 50 to 796 pg/ml, respectively.",Pulmonary extraction and pharmacokinetics of prostaglandin E1 during continuous intravenous infusion in patients with adult respiratory distress syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3337471/),[pg] / [ml],50,186791,DB00770,Alprostadil
,3337471,pulmonary extraction ratio (Ep),The pulmonary extraction ratio (Ep) of PGE1 varied from 0.11 to 0.90 and was independent of dose but dependent on cardiac output.,Pulmonary extraction and pharmacokinetics of prostaglandin E1 during continuous intravenous infusion in patients with adult respiratory distress syndrome. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3337471/),,0.11 to 0.90,186792,DB00770,Alprostadil
greater,3337471,Ep,"Nine of 10 patients with AaPO2/FlO2 below 510 mm Hg had Ep greater than 0.7 and high pulmonary intrinsic clearance for PGE1 (ca. 250 L/min), but all 4 patients with AaPO2/FlO2 above 510 mm Hg had Ep less than 0.6 and low intrinsic clearance (ca. 37 L/min or less).",Pulmonary extraction and pharmacokinetics of prostaglandin E1 during continuous intravenous infusion in patients with adult respiratory distress syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3337471/),,0.7,186793,DB00770,Alprostadil
,3337471,pulmonary intrinsic clearance,"Nine of 10 patients with AaPO2/FlO2 below 510 mm Hg had Ep greater than 0.7 and high pulmonary intrinsic clearance for PGE1 (ca. 250 L/min), but all 4 patients with AaPO2/FlO2 above 510 mm Hg had Ep less than 0.6 and low intrinsic clearance (ca. 37 L/min or less).",Pulmonary extraction and pharmacokinetics of prostaglandin E1 during continuous intravenous infusion in patients with adult respiratory distress syndrome. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3337471/),[l] / [min],250,186794,DB00770,Alprostadil
less,3337471,Ep,"Nine of 10 patients with AaPO2/FlO2 below 510 mm Hg had Ep greater than 0.7 and high pulmonary intrinsic clearance for PGE1 (ca. 250 L/min), but all 4 patients with AaPO2/FlO2 above 510 mm Hg had Ep less than 0.6 and low intrinsic clearance (ca. 37 L/min or less).",Pulmonary extraction and pharmacokinetics of prostaglandin E1 during continuous intravenous infusion in patients with adult respiratory distress syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3337471/),,0.6,186795,DB00770,Alprostadil
,3337471,intrinsic clearance,"Nine of 10 patients with AaPO2/FlO2 below 510 mm Hg had Ep greater than 0.7 and high pulmonary intrinsic clearance for PGE1 (ca. 250 L/min), but all 4 patients with AaPO2/FlO2 above 510 mm Hg had Ep less than 0.6 and low intrinsic clearance (ca. 37 L/min or less).",Pulmonary extraction and pharmacokinetics of prostaglandin E1 during continuous intravenous infusion in patients with adult respiratory distress syndrome. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3337471/),[l] / [min],37,186796,DB00770,Alprostadil
,2500461,AUC(0-4),"Relative to fasting conditions administration of misoprostol with antacid resulted in reduced bioavailability, as manifested by lower AUC(0-4) values from (mean +/- SD; n = 12) 417 +/- 135 to 349 +/- 108 pg.hr/ml (P less than 0.05), without significant changes in the rate of absorption (tmax = 14 +/- 8 [fasting] vs. 20 +/- 14 min [with antacid]).","Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2500461/),[h·pg] / [ml],417,194979,DB00770,Alprostadil
,2500461,AUC(0-4),"Relative to fasting conditions administration of misoprostol with antacid resulted in reduced bioavailability, as manifested by lower AUC(0-4) values from (mean +/- SD; n = 12) 417 +/- 135 to 349 +/- 108 pg.hr/ml (P less than 0.05), without significant changes in the rate of absorption (tmax = 14 +/- 8 [fasting] vs. 20 +/- 14 min [with antacid]).","Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2500461/),[h·pg] / [ml],349,194980,DB00770,Alprostadil
,2500461,tmax,"Relative to fasting conditions administration of misoprostol with antacid resulted in reduced bioavailability, as manifested by lower AUC(0-4) values from (mean +/- SD; n = 12) 417 +/- 135 to 349 +/- 108 pg.hr/ml (P less than 0.05), without significant changes in the rate of absorption (tmax = 14 +/- 8 [fasting] vs. 20 +/- 14 min [with antacid]).","Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2500461/),min,14,194981,DB00770,Alprostadil
,2500461,tmax,"Relative to fasting conditions administration of misoprostol with antacid resulted in reduced bioavailability, as manifested by lower AUC(0-4) values from (mean +/- SD; n = 12) 417 +/- 135 to 349 +/- 108 pg.hr/ml (P less than 0.05), without significant changes in the rate of absorption (tmax = 14 +/- 8 [fasting] vs. 20 +/- 14 min [with antacid]).","Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2500461/),min,20,194982,DB00770,Alprostadil
,2500461,Cmax,"The observed Cmax values were also reduced (from 811 +/- 317 to 689 +/- 315 pg/ml), however, the difference was not statistically significant.","Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2500461/),[pg] / [ml],811,194983,DB00770,Alprostadil
,2500461,Cmax,"The observed Cmax values were also reduced (from 811 +/- 317 to 689 +/- 315 pg/ml), however, the difference was not statistically significant.","Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2500461/),[pg] / [ml],689,194984,DB00770,Alprostadil
,2500461,Cmax,Relative to fasting conditions food decreased misoprostol acid Cmax from 811 +/- 317 to 303 +/- 176 pg/ml (P less than 0.05) and increased tmax from 14 +/- 8 to 64 +/- 79 min (P less than 0.05): the AUC changes remained statistically insignificant from 417 +/- 135 to 373 +/- 111 pg.hr/ml.,"Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2500461/),[pg] / [ml],811,194985,DB00770,Alprostadil
,2500461,Cmax,Relative to fasting conditions food decreased misoprostol acid Cmax from 811 +/- 317 to 303 +/- 176 pg/ml (P less than 0.05) and increased tmax from 14 +/- 8 to 64 +/- 79 min (P less than 0.05): the AUC changes remained statistically insignificant from 417 +/- 135 to 373 +/- 111 pg.hr/ml.,"Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2500461/),[pg] / [ml],303,194986,DB00770,Alprostadil
,2500461,tmax,Relative to fasting conditions food decreased misoprostol acid Cmax from 811 +/- 317 to 303 +/- 176 pg/ml (P less than 0.05) and increased tmax from 14 +/- 8 to 64 +/- 79 min (P less than 0.05): the AUC changes remained statistically insignificant from 417 +/- 135 to 373 +/- 111 pg.hr/ml.,"Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2500461/),min,14,194987,DB00770,Alprostadil
,2500461,tmax,Relative to fasting conditions food decreased misoprostol acid Cmax from 811 +/- 317 to 303 +/- 176 pg/ml (P less than 0.05) and increased tmax from 14 +/- 8 to 64 +/- 79 min (P less than 0.05): the AUC changes remained statistically insignificant from 417 +/- 135 to 373 +/- 111 pg.hr/ml.,"Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2500461/),min,64,194988,DB00770,Alprostadil
,2500461,AUC,Relative to fasting conditions food decreased misoprostol acid Cmax from 811 +/- 317 to 303 +/- 176 pg/ml (P less than 0.05) and increased tmax from 14 +/- 8 to 64 +/- 79 min (P less than 0.05): the AUC changes remained statistically insignificant from 417 +/- 135 to 373 +/- 111 pg.hr/ml.,"Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2500461/),[h·pg] / [ml],417,194989,DB00770,Alprostadil
,2500461,AUC,Relative to fasting conditions food decreased misoprostol acid Cmax from 811 +/- 317 to 303 +/- 176 pg/ml (P less than 0.05) and increased tmax from 14 +/- 8 to 64 +/- 79 min (P less than 0.05): the AUC changes remained statistically insignificant from 417 +/- 135 to 373 +/- 111 pg.hr/ml.,"Effects of food and antacid on oral absorption of misoprostol, a synthetic prostaglandin E1 analog. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2500461/),[h·pg] / [ml],373,194990,DB00770,Alprostadil
,11992097,minimum effective dose,The minimum effective dose for complete erection was 10 mcg.,"The efficacy, safety and tolerability of intracavernous PNU-83757 for the treatment of erectile dysfunction. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11992097/),mcg,10,201650,DB00770,Alprostadil
,3424870,peak 3H levels,"After oral administration of 3H-enisoprost (450 micrograms) to five healthy men, as a solution in capsules, peak 3H levels of 5624 +/- 566 pg equiv./ml (mean +/- S.E.M.) were reached within one hour.","Disposition of 3H-enisoprost, a gastric antisecretory prostaglandin, in healthy humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3424870/),[equiv·pg] / [ml],5624,202734,DB00770,Alprostadil
,3424870,peak concentrations,"2. Enisoprost was rapidly de-esterified to SC-36067 [(+/-)11 alpha, 16 zeta-dihydroxy-16-methyl-9-oxoprost-4Z, 13E-dien-1-oic acid], a pharmacologically active analogue, which reached peak concentrations of 651 +/- 200 pg/ml within 20 min of dosing.","Disposition of 3H-enisoprost, a gastric antisecretory prostaglandin, in healthy humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3424870/),[pg] / [ml],651,202735,DB00770,Alprostadil
,3424870,half-life,"SC-36067 was eliminated metabolically, with a half-life of 1.61 h, by a combination of beta-oxidation, omega-oxidation and 9-keto-reduction.","Disposition of 3H-enisoprost, a gastric antisecretory prostaglandin, in healthy humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3424870/),h,1.61,202736,DB00770,Alprostadil
,1608154,elimination half-life,"However, the mean elimination half-life of bupivacaine was significantly longer in patients with TMP [5.0 +/- 1.7 (SD) hr] compared with those with PGE1 (3.1 +/- 1.4 hr).",[Pharmacokinetics of epidurally administered bupivacaine during prostaglandin E1- or trimetaphan-induced hypotension]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608154/),h,5.0,208111,DB00770,Alprostadil
,1608154,elimination half-life,"However, the mean elimination half-life of bupivacaine was significantly longer in patients with TMP [5.0 +/- 1.7 (SD) hr] compared with those with PGE1 (3.1 +/- 1.4 hr).",[Pharmacokinetics of epidurally administered bupivacaine during prostaglandin E1- or trimetaphan-induced hypotension]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608154/),h,3.1,208112,DB00770,Alprostadil
,1608154,total clearance,The total clearance of bupivacaine was greater in patients with PGE1 (345 +/- 150 ml.min-1) compared with those with TMP (248 +/- 66 ml.min-1).,[Pharmacokinetics of epidurally administered bupivacaine during prostaglandin E1- or trimetaphan-induced hypotension]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608154/),[ml] / [min],345,208113,DB00770,Alprostadil
,1608154,total clearance,The total clearance of bupivacaine was greater in patients with PGE1 (345 +/- 150 ml.min-1) compared with those with TMP (248 +/- 66 ml.min-1).,[Pharmacokinetics of epidurally administered bupivacaine during prostaglandin E1- or trimetaphan-induced hypotension]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608154/),[ml] / [min],248,208114,DB00770,Alprostadil
<,22911340,serum trough concentration,"Patients were evaluated to determine whether they achieved a serum trough concentration of <1 mg/L, and differences in patient characteristics were noted for those who achieved an appropriate trough concentration and those who did not.",Use of 4-mg/kg/24-hour empiric aminoglycoside dosing in preoperative neonates with congenital heart disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22911340/),[mg] / [l],1,225943,DB00770,Alprostadil
<,22911340,trough gentamicin concentration,"Twenty-eight patients met study criteria, and 22% of patients had a trough gentamicin concentration of <1 mg/L at a mean (SD) time of 23.6 (0.3) hours after a dose.",Use of 4-mg/kg/24-hour empiric aminoglycoside dosing in preoperative neonates with congenital heart disease. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22911340/),[mg] / [l],1,225944,DB00770,Alprostadil
,22911340,time,"Twenty-eight patients met study criteria, and 22% of patients had a trough gentamicin concentration of <1 mg/L at a mean (SD) time of 23.6 (0.3) hours after a dose.",Use of 4-mg/kg/24-hour empiric aminoglycoside dosing in preoperative neonates with congenital heart disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22911340/),h,23.6,225945,DB00770,Alprostadil
,1762057,ED50,"SC-46275 exhibited potent antisecretory activity when administered directly into the gastric pouch, the ED50 being 0.01 micrograms/kg.","SC-46275: a potent, long-acting gastric antisecretory prostaglandin with low oral bioavailability in the dog. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1762057/),[μg] / [kg],0.01,240457,DB00770,Alprostadil
,19137119,half-life,Lubiprostone reaches peak plasma concentrations within approximately 1 h and has a half-life of 0.9-1.4 h.,Lubiprostone--a novel treatment for irritable bowel syndrome with constipation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19137119/),h,0.9-1.4,248383,DB00770,Alprostadil
